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Monocytes play critical roles in the pathogenesis of chronic inflammatory diseases, 
including autoimmunity as well as in the innate response to infections. Human 
monocytes are heterogeneous and generally classified into three subsets based on 
CD14 and CD16 expression. Although increasing evidences suggest that three 
monocyte subsets have distinct functions in inflammatory conditions, little is 
known about their roles in pathogenesis of autoimmune diseases. To address this 
issue, I investigated the phenotypic and functional characteristics of monocytes in 
the synovial fluid (SF) and peripheral blood (PB) from patients with rheumatoid 
arthritis (RA). CD16 expression on CD14+ monocytes in the SF was significantly 
increased compared with the PB of RA patients and healthy controls, whereas 
CD14dimCD16+ monocytes were rarely observed in the SF. The majority of 
synovial monocytes constitutively expressed CD80, while peripheral monocytes 
did not express CD80 without stimulation. In addition, the expression of 
membrane-bound IL-15 was markedly elevated in the RA patients. The TLR 
expression between peripheral monocyte and synovial monocytes were distinct, 
monocytes from synovial fluid had increased TLR levels generally. To explore how 
synovial monocytes gain unique properties, PB monocytes were stimulated with 
various cytokines and TLR ligands. Interestingly, TGF-β is a potent inducer of 
CD16 expression on CD14+ monocytes, whereas expressions of CD80 and 
membrane-bound IL-15 were significantly elevated by IFN-γ exerting a synergistic 
effect with IL-15. The synovial monocytes were found to significantly promote 
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Th17 and Th1 responses in vitro, compared with PB monocytes from RA patients. 
The findings in this study suggest the possible role for cytokine milieu of the SF in 
giving unique features to synovial monocytes and their important roles in affecting 
inflammatory T-cell response in RA. 
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Monocytes are circulating mononuclear phagocytes that have been generally 
considered as systemic precursors for tissue macrophages and inflammatory 
dendritic cells (DCs). Blood monocytes play critical roles in host defense against 
infection of microbes, fungi, virus and parasites by phagocytosis and production of 
reactive oxygen species (ROS) and secrete proinflammatory cytokines such as, 
TNF-α, IL-6, and IL-1β (1). More recently, monocytes are also implicated in 
various inflammatory diseases, including atherosclerosis (2).   
In mice and humans, monocytes are classified into two major populations on the 
basis of their phenotypes. Traditionally, human monocytes have been defined as 
cells that express CD14 which is co-receptor of lipopolysaccharide (LPS). 
However Ziegler-Heitbrock and colleagues identified a minor population of human 
monocytes which express CD16 (FcγRIII) and demonstrated differential 
functionality between two CD14+ and CD16+ monocytes.(3) On the basis of in vivo 
mouse studies, murine monocytes are divided into two subsets; LY6Chigh (Gr1+) 
and LY6Clow (Gr1-) monocytes. The former population specializes in 
proinflammatory and antimicrobial roles, whereas the latter population involve in 
patrolling the blood vessel lumen by associating with the vascular endothelium and 
in promoting wound healing (4-6). Although two monocyte populations in human 
and mice are not precisely overlapping, their contribution to immune responses 
seems to be similar (7). Human CD14+ monocytes, which are called “classical 
monocytes”, represent 80-90% of blood monocytes and express high level of 
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chemokine receptor CCR2 and low level of CX3CR1. Their phenotype and 
function resembles those of the murine LY6Chigh (Gr1+) monocytes. In contrast to 
CD14+ monocytes, CD16+ monocytes are characterized by CX3CR1highCCR2low 
and are similar to the murine LY6Clow (Gr1-) monocytes which are called 
“patrolling monocytes” (8, 9). 
More recently, human monocytes expressing CD16 are suggested to be 
subdivided further into two subsets, CD14+CD16+ and CD14dimCD16+ monocytes, 
on the basis of level of surface CD14 expression, their gene expression profiles, 
and responses against external stimulus (1). The CD14+CD16+ monocytes share 
many features of “classical” CD14+CD16- monocytes having high capacity of 
phagocytosis and producing pro-inflammatory cytokines in response to ligand of 
TLR2 and TLR4. Meanwhile, the CD14dimCD16+ monocytes rarely show capacity 
of phagocytosis but selectively produce TNF-α and IL-1β in response to virus or 
immune complexes containing nucleic acid stimuli, through TLR7 and TLR8 
mediated signaling pathway (1). Of importance, CD16+ monocytes including 
CD14+CD16+ and CD14dimCD16+ monocyte populations expand in peripheral 
blood of patients with acute and chronic inflammation (10-12) but the actual 
function of the CD16+ monocytes still remains elusive. 
There is accumulating evidence that inflammatory monocytes could play 
important roles in induction and shaping of T-cell responses (6, 10). Indeed, several 
studies have recently demonstrated that TLR-stimulated monocytes are required for 
optimal induction of IL-17-producing CD4 T-cells (Th17 cells) which have critical 
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roles of pathogenesis of autoimmune diseases. These finding indicate that the 
monocytes are closely linked to regulation of the adaptive immune responses (13, 
14). It has been well documented that CD4 helper T cells (hereafter Th17 cells) 
selectively producing IL-17 are linked to many chronic inflammation and 
autoimmune diseases, including multiple sclerosis (MS), psoriasis, inflammatory 
bowel diseases (IBD), and rheumatoid arthritis (RA) (15). In humans, in vitro Th17 
differentiation requires stimulation via CD3 and CD28 in the presence of IL-1β, 
IL-6, and IL-23, whereas murine Th17 cells can be induced by CD3/CD28 
stimulation with TGF-β and IL-6 alone. Human monocytes stimulated through 
certain TLRs produce high levels of IL-1β, IL-6, and IL-23 and the environment 
milieu by these cytokines can have important effects on the polarization and 
expansion of T cells as antigen-presenting cells (APCs) do (13, 16). 
Rheumatoid Arthritis (RA) is representative systemic autoimmune disease and 
chronic inflammatory disease that targets synovial membrane (14). There have 
been many studies about pathogenesis of RA, several candidates are shown up like 
genetic factors, infection and abnormal secretion of hormones, but the exact 
immune mechanism still remains unclear. Since the frequency of CD16+ monocytes 
in RA patients is significantly elevated and they produce enormous amounts of 
TNF-α in response to TLR2 stimulation (9, 17), CD16+ monocytes are implicated 
in pathophysiology of RA but their pathogenic roles need to be clear, especially 
their modulatory roles for T-cell responses. Of important, the CD16+ monocytes 
expressing high level of surface CX3CR1 are seemed to migrate to synovium by 
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CX3CR1-CX3CL1 interaction (18, 19). 
Although increasing evidences suggest that inflammatory CD16+ monocytes 
have distinct functions in inflammatory conditions, little is known about their roles 
in pathogenesis of autoimmune disorders including RA. To address this issue, I 
investigated the phenotypic and functional characteristics of monocytes in the 
synovial fluid (SF) and peripheral blood (PB) from patients with RA and healthy 
controls. In present studies, my findings suggest the possible role for cytokine 
milieu of the SF in giving unique features to synovial monocytes and their 










Material and Methods 
Cell isolation from healthy controls (HC) and RA patients 
Peripheral blood and synovial fluid of RA patients were obtained from the 
Department of Internal Medicine, Chungnam National University Hospital. 
Peripheral blood of healthy volunteers was drawn after obtaining informed consent 
at Seoul National University College of Medicine (IRB No.1109-055-378). 
Mononuclear cells were isolated from peripheral blood or synovial fluid by density 
gradient centrifugation (Bicoll separating solution; BIOCHROM Inc, Cambridge, 
UK). Monocytes were positively separated with CD14 microbeads (Miltenyi 
Biotec Inc, Auburn, CA) from peripheral blood mononuclear cells (PBMC) and 
synovial fluid mononuclear cells (SFMC). CD4 memory T cells were negatively 
purified with human memory CD4+ T cell enrichment kit (EasySep negative 
selection; STEMCELL technologies Inc, Vancouver, Canada). 
Flow cytometric analysis 
PBMC and SFMC were stained for 30min at 4 degree with anti-CD3- 
allophycocyanin (APC), anti-CD14-APC, anti-CD19-APC, anti-CD56-APC, anti-
CD3-APC-cyanin 7 (Cy7), anti-CD14-APC-Cy7, anti-HLA-DR-fluorescein 
isothiocyanate (FITC), anti-CD68-phycoerythrin (PE), anti-CD80-PE, anti-CD86-
PE, anti-CD16-PE- cyanin 5 (Cy5), anti-CD4-PE-Cy5, (all from BD Bioscience, 
San Jose, CA), anti-CX3CR1-PE, anti-TLR4-PE (all from eBioscience Inc, San 
Diego, CA), anti-CCR2-PE, anti-IL-15-PE (all from R&D systems, Minneapolis, 
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MN), PE-TLR7 (IMGENEX corp, San Diego, CA), and PE-TLR8 (Abcam plc, 
Cambridge, MA).Stained cells were acquired by a BD LSRII (BD bioscience) and 
analyzed by using Flowjo software (ver. 9.0; Tree star, OR). 
Cell culture 
Purified monocytes and CD4 memory T cells from HC and RA patients were 
cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 
1% penicillin/streptomycin and 1% L-glutamine. Purified monocytes were seeded 
at 5 ☓ 103 into U-bottomed 96-well plate in the presence of soluble anti-CD3 
antibody (1μg/ml; BD bioscience), anti-CD28 antibody (1μg/ml; BD bioscience), 
and LPS (100ng/ml; Sigma-Aldrich Inc, St. Louis, MO). After 1hr incubation, 2.5 
X 104 CD4 memory T cells were added into each well, and co-cultured with LPS-
activated monocytes for 7 days. In some experiments, purified monocytes were 
treated with TGF-β (10ng/ml; R&D systems) in the presence or absence of 
recombinant human IFN-γ (25ng/ml; ebioscience) and/or recombinant human IL-
15 (25ng/ml; R&D systems) in 5ml polypropylene tube (BD falcon) for 18hrs, 
followed by FACS staining with antibodies to CD14, CD16, and HLA-DR. For 
monocytes treated with various cytokines, RPMI 1640 medium supplemented with 
10% human AB serum was used to avoid any stimulation of monocytes with FBS. 
Intracellular cytokine staining (ICS) and enzyme-linked immunosorbent assay 
(ELISA) 
For intracellular cytokine staining, CD4 T cells co-cultured with monocytes for 7 
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days were re-stimulated 6 hours with PMA (50ng/ml; Sigma-Aldrich) and 
ionomycin (1ug/ml; Sigma-Aldrich) in the presence with Golgiplug (BD 
bioscience) for last 4 hours. Cells were fixed and permeablized with BD 
Cytofix/Cytoperm™ kit. Cells were stained with antibodies to anti-IL-17A-PE, 
anti-IFN-γ-PE-Cy7, anti-IL-6-PE (all from eBioscience), anti-TNF-α-V450 (BD 
bioscience), and anti-IL-1β-Alexa 647 (Biolegend Inc, San Diego, CA) followed 
by analysis on a BD LSRII. In some experiments, intracellular cytokine staining 
was performed with freshly isolated PBMC and SFMC from RA patients. Various 
cytokines (IL-6, IL-1β, IL-17A, IFN-γ, and TNF-α) in co-culture supernatant were 
quantified by commercial ELISA kits (eBioscience for IL-6, IL-1β, IL-17A, and 
TNF-α and Biolegend for IFN-γ). The measurement of OD (Optical density value) 
was performed using DTX 880/multimode detector (Beckman coulter). 
Quantitative RT-PCR 
Total RNA was extracted from freshly isolated or co-cultured cells using TRIzol 
reagents (Invitogen by life technologies corp, Grand Island, NY) and cDNA was 
synthesized by GoScript reverse transcription system (Promega corp, Madison, WI). 
Primers were designed using the OligoPerfect Designer (Invitrogen; sequences in 
Table 1) or adopted from previously described primer sequences [Ref]. Real-time 
quantitative reverse-transcription-polymerase chain reaction (RT-PCR) was 
performed in triplicate on a 7500 PCR system (Applied Biosystems) using the 
iQ™SYBR® Green supermix (Bio-Rad Laboratories Inc, Hercules, CA). The 
levels of gene expression were normalized to the expression of ACTINB. The 
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comparative CT method (ΔΔCT) was used for the quantification of gene expression.  
Table 1. Gene-specific primers used in the real-time RT-PCR reactions :  
Gene Product size Primer sequence 
CD16A 210bp Forward 5’- GCT CCG GAT ATC TTT GGT GA-3’ Reverse 5’-CTC CCT GGC ACT TCA GAG TC-3’ 
CD68 152bp Forward 5’-ACT GAA CCC CAA CAA AAC CA-3’ Reverse 5’-TTG TAC TCC ACC GCC ATG TA3’ 
CD80 215bp Forward 5’-GGG AAA GTG TAC GCC CTG TA-3’ Reverse 5’-GCT ACT TCT GTG CCC ACC AT-3’ 
CD86 211bp Forward 5’-TGG AAC CAA CAC AAT GGA GA-3’ Reverse 5’-GGT TGC CCA GGA ACT TAC AA-3’ 
CX3CR1 198bp Forward 5’-GCA AGA AGC CCA AGA GTG TC-3’ Reverse 5’-ATG CTG ATG ACG GTG ATG AA-3’ 
IL-15Rα 212bp Forward 5’-ACC TTC CAC AGG AAC CAC AG-3’ Reverse 5’-AGG TAG CAT GCC AGG AGA GA-3’ 
TLR2 176bp Forward 5’-ATT GTG CCC ATT GCT CTT TC-3’ Reverse 5’-CTG CCC TTG CAG ATA CCA TT-3’ 
TLR4 198bp Forward 5’-TC TTC AAC CAG ACC TCT ACA TTC CA-3’ Reverse 5’- GGA ACA TCC AGA GTG ACA TCA CAG-3’ 
TLR7 207bp Forward 5’-TCA CTC CAT GCC ATC AAG AA-3’ Reverse 5’-ACC ATC TAG CCC CAA GGA GT-3’ 
TLR8 111bp Forward 5’-TTT TCT TCA TTG GGC CAA AC-3’ Reverse 5’-GAA TGG CTG AAA ATT CAG TTC C-3’ 
 
Statistical analysis 
A paired t-test was done to analyze data using Graph pad Prism 5 (GraphPad 
Software Inc, La Jolla, CA) and Microsoft Excel 2010. P values of less than .05 




Increased expression of CD16 on monocytes of RA patients 
To investigate whether the frequency of CD16+ monocyte is changed in RA 
patients enrolled in this study, I first analyzed mononuclear cells isolated from 
peripheral blood (PB) and synovial fluid (SF) of RA patients or healthy controls by 
multicolor flow cytometry. Since majority of human NK cells and B cells also 
express CD16 and HLA-DR on their surface, respectively, flow cytometric analysis 
was carefully performed by following gating strategy (Fig. 1). Monocytes were 
identified on the basis of their characteristic forward- and side-scatter profile. 
Within this gate, monocytes were defined as HLA-DR+ cells which do not express 
B cell (CD19), T cell (CD3), or NK cell (CD56) lineage markers. Among the HLA-
DR+ cells, three human monocyte populations were well separated by CD14 and 
CD16 expression (Fig. 1A). In healthy controls, approximately 85% of PB 
monocytes represented “classical” CD14+CD16- monocyte population, whereas the 
frequency of CD16+ monocytes was under 10% of total PB monocytes. Consistent 
with previous reports (1, 3, 11), the CD16+ monocytes in healthy controls could be 
further subdivided into “inflammatory” or “intermediate” CD14+CD16+ (62.80 % 
of CD16+ monocytes) and “nonclassical” or “patrolling” CD14dimCD16+ (37.20 % 
of CD16+ monocytes) (Fig. 1A and 2A). The frequency of CD16+ monocytes 
(15.52 ± 10.79 %) was significantly increased in peripheral blood of RA patients 
compared to healthy controls (8.60 ± 5.34 %). More importantly, this change was 
due to the expansion of CD14+CD16+ population (12.77 ± 10.27 % versus 5.29 ± 
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3.75%) but not CD14dimCD16+ population (2.75 ± 2.50 % versus 3.31 ± 3.0 %). 
The frequency of PB CD14dimCD16+ monocytes in RA patient was rather slightly 
decreased compared to healthy controls thought it was not statistically significant 
(Fig 1B and 2A).  
In synovial fluid, CD14+CD16- monocytes were significantly reduced when 
compared to peripheral blood of same patients (59.90 ± 22.57 % versus 82.06 ± 
11.28 %; p<0.004). This reduction seems to be associated with increase of CD14-
CD16-HLA-DR+ cells as well as CD14+CD16+ monocytes. Increase of CD16+ 
monocytes (23.15 ± 15.22 %) were more markedly observed in synovial fluid of 
RA patients. There was a trend towards higher frequency of CD16+ monocyte in 
synovial fluid than that in peripheral blood of same patient (p=0.11; 12 of 15 
patients) (Fig 1B and 2A). Among SF CD16+ monocytes, the proportion of 
CD14+CD16+ monocytes (88.73 ± 9.41 %) was substantially higher than that in 
peripheral blood of RA patients (75.62 ± 22.70 %) or healthy controls (63.80 ± 
25.18 %), suggesting that increase of SF CD16+ monocytes mainly results from 
expansion of CD14+CD16+ monocytes. Increased expression of CD16 on SF 
monocytes was confirmed at gene level by real time RT-PCR. The mRNA level of 
the CD16 gene were higher in purified CD14+ monocytes from synovial fluids than 
those from peripheral blood of same RA patient (Fig. 2A). 
Since several studies revealed that CD16+ monocytes expanded in inflammatory 
conditions, I next asked whether the frequency of CD14+CD16+ monocytes 
correlated with known RA disease parameters such as DAS28, ESR, and CRP. No 
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association with the parameters was observed in present study so far. 
Phenotypic characteristics of PB and SF monocytes from RA patients 
As mentioned previously, different monocyte subsets have characteristic 
chemokine receptor and regulatory molecule expression profiles, indicating their 
differential migratory capability and functionality (8, 9). To investigate expression 
profiles of the surface molecules, including chemokine receptors, co-stimulatory 
molecules, and etc, on monocytes of RA patients, the expression profiles were 
compared among PB monocytes from healthy or RA patients and SF monocytes 
from RA patients using multicolor flow cytometric analysis. 
Consistent with previous reports (4, 7), CD14+ monocytes in healthy control 
express higher CCR2 and lower but still considerable level of CX3CR1. In the case 
of CD14dimCD16+ monocytes, CX3CR1highCCR2- phenotype was observed. Co-
stimulatory molecule CD86 was constitutively expressed at high level but CD80 
was barely expressed on PB monocytes of healthy controls (Fig 3A). When 
compared to monocytes of healthy controls, CX3CR1 expression in RA patients 
was significantly decreased in PB CD16+ monocytes and even more decreased in 
SF CD16+ monocytes. Especially, CX3CR1 expression levels of SF monocytes in 
RA patients were very similar among three monocyte populations. CCR2 and co- 
CD86 expression levels on monocytes did not significantly differ between healthy 
controls and RA patients. Consistent with FACS analysis, the gene expression of 
CX3CR1 on RA SF monocytes was reduced at 50% (Fig 3B-D). 
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The most outstanding difference was the expression of co-stimulatory molecules 
CD80 on SF monocytes but not on PB monocytes of RA patients. As 
abovementioned, PB monocytes did not express CD80 in healthy control and even 
in RA patients (Fig. 4A). Elevated CD80 expression was a unique feature of SF 
monocyte of RA and this induction was confirmed at gene expression level by real-
time RT-PCR (Fig. 4B). CD80 gene expression of SF monocyte was around 40 
folds higher than that of PB monocytes in same RA patients. 
HLA-DR was a MHC class II molecule that gives ‘first signal’ to T cell receptor 
(TCR) on CD4 T cells. Antigen presenting cells (macrophage, B cells, and 
dendritic cells) typically express HLA-DR. Upon stimulation, increased level of 
HLA-DR expression was observed in antigen presenting cells as well as various 
cells including T cells. Of importance, enhanced HLA-DR expression was seen on 
SF monocytes (Fig. 4C) and this increase was even more marked in CD14+CD16+ 
than CD14+CD16- monocytes (Fig. 4D). 
Interleukin-15 (IL-15) is one of the common γ chain cytokines and exists in 
membrane-bound form usually bound with IL-15 receptor alpha (IL-15Rα) on the 
surface of monocytes or dendritic cells. The membrane-bound IL-15 (mIL-15) 
regulates activation and proliferation of T cells and NK cells, and up-regulation of 
mIL-15 has a central role in the several autoimmune and chronic inflammatory 
diseases (20). Thus I measured mIL-15 expression on PB monocytes from healthy 
controls and RA patients and on SF monocytes from RA patients (Fig. 5A, 
representative data). PB monocytes in RA patients showed a trend toward higher 
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mIL-15 expression level compared to healthy controls. Intriguingly, mIL-15 
expression on monocytes was rather reduced on SF monocytes in RA patients. The 
level of mIL-15 expression on SF monocytes was comparable to that on PB 
monocytes of healthy controls (Fig. 5B).  
Distinct TLR expression profiles of PB and SF monocytes from RA patients 
Toll like receptors (TLRs) are a family of proteins that play critical roles in innate 
immune system including monocytes. Several studies have recently demonstrated 
that TLR-stimulated monocytes are required for optimal induction of Th17 cells 
which are involved in pathogenesis of various autoimmune diseases. Thus I 
analyzed various TLR expressions on monocytes from blood and synovial fluid of 
RA patients or healthy controls. Among TLRs tested in this study, TLR8 gene was 
markedly elevated in PB monocytes in RA patients when compared to healthy 
controls (Fig. 6A). When compared between PB and SF monocytes in RA patients, 
the levels of TLR4 gene expression were enhanced by approximately 10 times in 
monocytes from synovial fluid (Fig. 6B). 
Effect of various cytokines which can induce distinct phenotype of monocytes 
in RA patients 
CD16+ monocytes expand in various acute and chronic inflammatory diseases. 
Certain cytokine milieus have been suggested to induce CD16 on monocytes in 
inflammatory conditions (21-23). To explore possible mechanism underlying CD16 
induction on monocytes, I treated various classes of cytokines and ligands for TLR 
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on CD14+ monocytes purified from healthy control and analyzed the change of 
CD16 level. TLR activation with LPS (ligand for TLR4) and R848 (ligand for 
TLR7 and TLR8) rather down-regulated CD16 expression on monocytes and 
proinflammatory cytokines, such as IL-1β, IL-6, and TNF-α cytokines, did not 
change the CD16 expression. Among the cytokines tested, TGF-β treatment for 18 
hours clearly elevated CD16 expression on PB CD14+ monocytes of healthy 
controls (Fig. 7A). Approximately 20% of monocytes induced CD16 molecules on 
their cell surface compared to no treated monocytes (Fig. 7B). Next I explored 
cytokines which are able to induce CD80 and mIL-15 on monocytes. Since TGF-β 
was the key inducer of CD16 on monocytes, other cytokines were treated on 
monocytes in the presence of TGF-β. The expression of CD80 was significantly 
increased in purified CD14+ monocytes which were treated with IFN-γ in the 
presence of TGF-β (Fig. 8). The treatments of TGF-β alone had no effects on 
expression level of CD80. The expression of mIL-15 was enhanced by treatment 
with IFN-γ or IL-15 regardless of TGF-β treatment. Of interest, treatment of IL-15 
had a synergetic effect on expression of mIL-15 when treated with IFN-γ (Fig. 9A). 
Monocytes treated with IFN-γ caused not just only increase of mIL-15 expression 
but also induction of IL-15Rα (Fig. 9B) which can do trans-presentation of mIL-15 
to effector cells. These findings suggest that the distinct phenotype of monocytes 
from RA patients may be induced under certain cytokine milieu. 
The SF monocytes significantly promoted Th17 and Th1 responses in vitro, 
compared with PB monocytes from RA patients. 
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The findings so far clearly showed that SF monocytes in RA patients have distinct 
phenotype. Next I investigated whether these SF monocytes in RA patient have 
unique capacity to modulate and shape T-cell responses. To answer this question, 
CD14+ monocytes (including CD14+CD16- and CD14+CD16+ monocytes) and CD4 
memory T cells were highly purified from peripheral blood and synovial fluids in 
the same patients. Purified PB and SF CD4 memory T cells were criss-cross co-
cultured for 7 days with PB or SF CD14+ monocytes in the presence of soluble 
anti-CD3, anti-CD28 antibodies and LPS (Fig. 10A). Intracellular cytokine staining 
(ICS) on day 7 showed the frequencies of IL-17A and/or IFN-γ producing CD4 T 
cells purified from peripheral blood were significantly higher in the culture 
conditions with SF monocytes than PB monocytes in RA patients (Fig. 10B). 
Consistent with ICS data, the amount of IL-17A in the culture supernatant was 
significantly increased when PB CD4 memory T cells were co-cultured with SF 
monocytes (Fig. 11). In this culture condition, higher amount of IFN-γ was also 
seen but did not reached to statistical significance. Taken together, monocytes 
derived from synovial fluid have higher capacity to induce production of cytokines 







Figure 1. The strategy of gating purified monocytes using flow cytometry. 
Flow cytometric analysis of (A) peripheral blood monocytes (PBMO) from healthy 
controls and (B) monocytes from peripheral blood (left) or synovial fluid (SFMO, 







Figure 2. Monocytes derived from synovial fluid of RA patients had increased 
expression of CD16. 
(A) The frequency (%) of each subsets which were subdivided by differential 
expressions of CD14 and CD16 on monocytes. (B) Quantitative PCR analysis of 








Figure 3. The expressions of surface molecules on monocytes derived from RA 
patients and healthy controls. 
(A) Representative flow cytometric analysis of CX3CR1, CD80, CD86, CD68 and 
CCR2 expression on monocytes from peripheral blood of healthy control. (B) 
CX3CR1, CD86 and CCR2 expression on monocytes from peripheral blood of RA 
patients and healthy controls and (C) synovial fluid of RA patients. (D) Relative 
gene expressions of CD68, CD86, and CX3CR1 in isolated monocytes from 














Figure 4. The levels of CD80 and HLA-DR expression were markedly elevated 
in monocyte derived from synovial fluid of RA patients.  
(A) Flow cytometric analysis of CD80 expression among PBMO in healthy 
controls, PBMO and SFMO in RA patients (Gray shade: isotype control). (B) 
Relative gene expression of CD80 in isolated monocytes from peripheral blood and 
synovial fluid of RA patients (n=5). (C) Comparison of MFIs (mean fluorescent 
intensity) of HLA-DR between PBMO and SFMO in RA patients (n=19), (D) 






Figure 5. Membrane-bound IL-15 expression on surface of monocytes was 
elevated in peripheral blood of RA patients. 
(A) Membrane-bound IL-15 (mIL-15) expression on monocytes from peripheral 
blood of healthy controls, peripheral blood and synovial fluid of RA patients. (B) 





Figure 6. The differential expressions of TLRs in monocytes derived from 
healthy controls’ and RA patients’ peripheral blood or synovial fluid. 
(A) Relative gene expressions of TLRs in isolated monocytes from peripheral 
blood of healthy controls’ and RA patients’, and (B) compared with monocytes 





Figure 7. TGF-β treatment induced CD16 expression of monocytes in healthy 
controls. 
Isolated monocytes were treated with TGF-β (10ng/ml) in the absence or presence 
of other cytokines (IFN-γ or IL-15) for 18 hours in RPMI-1640 medium 
supplemented with 10% human AB serum. (A) Increased CD16 expression on 
monocyte after 18 hours-cytokine treatment (DAY0 indicates phenotype of 






Figure 8. CD80 expression was increased by IFN-γ treatment. 
(A) Flow cytometric analysis of CD80 expression on cytokine-treated monocytes 






Figure 9. Membrane-bound IL-15 expression on monocytes were elevated by 
IFN-γ exerting a synergistic effect with IL-15. 
(A) Flow cytometric analysis of mIL-15 expression on cytokine-treated monocytes 
(upper panel). MFI of mIL-15 on cytokine-treated monocytes (lower panel). (B) 





Figure 10. Cytokine production from CD4+ memory T cells after co-culture 
with monocytes derived from blood or synovial fluid of RA patients. 
Isolated monocytes and CD4+ memory T cell from peripheral blood (PB) and 
synovial fluid (SF) of RA patients were co-cultured with anti-CD3/CD28 and LPS 
for 7 days as indicated above. On day 7, cells were re-stimulated with PMA and 
ionomycin in the presence of BFA for 6 hrs and stained with antibodies to IL-17A 





Figure 11. The synovial monocytes significantly promoted Th17 and Th1 
responses in vitro, compared with peripheral blood monocytes from RA 
patients. 
Measurement of IL-17A (A) and IFN-γ (B) in the culture supernatant were 





Here I have demonstrated the distinct expression profile of surface molecules on 
monocytes in RA patients. Compared to healthy controls, PB and SF monocytes 
from RA patients have increased level of CD16. When co-cultured with PB CD4+ 
memory T cells from RA patients, significantly enhanced production of IL-17 and 
IFN-γ were observed in co-culture with SF monocytes but not with PB monocytes 
in RA patients.  
CD16 (FcγRIII) is the type of Fcγ receptor family which is mainly expressed on 
NK cells and neutrophils. It was well known that cross-linking with IgG antibodies 
to Fc domain induce various effector functions like phagocytosis, antibody 
production (ADCC) and production of inflammatory mediators (24, 25). In 
previous studies, CD16 molecules expressed on CD14+ monocytes in RA patients 
was suggested to involve in increased responsiveness to immune complex-
stimulation (26). The ligation of immune complex to CD16 on monocytes induces 
TNF-α and IL-1α and these cytokines are involved in the disease process as proved 
by the clinical efficacy of blocking TNF-α or IL-1 (27, 28). These findings have 
suggested the possible role of enhanced CD16 level on SF monocytes for 
inflammatory cytokine milieu of the synovial fluid. 
In this study, phenotype analysis with flow cytometry clearly showed that SF 
monocytes have elevated level of HLA-DR expression and CD80 when compared 
to PB monocytes, whereas CD86 expressions did not differ between SF and PB 
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monocyte in RA patients and even in healthy controls. The CD80 and CD86 are 
known to co-stimulatory molecules which are factors give ‘second signal’ to CD28 
or CTLA4 on T cells. CD86 is constitutively expressed on resting monocytes or 
activated B cells, whereas CD80 is not expressed on resting monocytes (29, 30). In 
addition, HLA-DR is a MHC class II cell surface molecule that gives ‘first signal’ 
to TCR(T cell receptor) on CD4 T cells, typically found in antigen presenting cells. 
Above two signals are necessary to induce immune response of CD4+ T cells, 
suggesting that the SF monocytes may have distinct phenotype which is suitable 
for activation of CD4+ T cells. 
 It is not known yet how and why SF monocytes have higher CD16 expression. 
Several possible explanations for this phenomenon can be offered; one is that 
CD16+ monocytes are selectively recruited into inflammatory synovial cavity, other 
is that circulating “classical” CD14+ monocytes migrate into synovial cavity and 
change (or differentiate) into “intermediate” or “proinflammatory” CD14+CD16+ 
monocytes under certain cytokine milieu of synovial fluid. To test the latter 
possibility, purified CD14+ monocytes were stimulated with various cytokines and 
TLR ligands. TGF-β treatment increased the level of CD16 expression on CD14+ 
monocytes purified from and IFN-γ treatment promotes upregulation of CD80 and 
mIL-15 levels. However, CD4+ memory T cells of healthy controls co-cultured 
with artificially modified monocytes expressing higher CD16, CD80, and mIL-15 
did not show capability to induce enhanced Th17 and Th1 responses which were 
markedly observed in the co-culture with PB CD4 T cells and SF monocytes in RA 
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patients (data not shown). It is suggested that there may be other intrinsic factors of 
SF monocytes to modulate and shape T cell immune responses. 
Collectively, this study demonstrates the phenotypic and functional characteristics 
of monocytes in SF and PB from patients with RA patients which may be affected 
by synovial fluid environment having critical roles of pathogenesis of RA. The 
findings in this study suggest the possible role for cytokine milieu of the SF in 
giving unique features to synovial monocytes and their important roles in affecting 
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단핵구는 감염에 대한 선천성 면역 반응에 관여할 뿐만 아니라, 
자가면역질환을 포함하는 만성 염증성 질병의 병인에도 중요한 역할을 
한다. 사람 단핵구는 일반적으로 CD14와 CD16의 발현 정도에 따라 세 
개의 아형으로 구분한다. 염증성 환경에서 이러한 세 개의 단핵구 
아형의 빈도 및 기능변화가 뚜렷한 나타난다는 연구결과들이 증가하고 
있음에도 불구하고, 자가면역질환의 병인에서 이들의 역할에 대해서는 
알려진 바가 많지 않다. 본 연구에서는 류마티스 관절염 환자에서 얻은 
관절활액과 말초혈액 내 단핵구의 표현형과 기능적 차이에 대해 
조사하였다. 류마티스 관절염 환자의 활액으로부터 분리한 CD14+ 
단핵구에서 CD16 발현이 동일 환자와 건강 대조군의 말초혈액 유래 
단핵구에 비해 유의적으로 증가되어있었던 반면에, CD14dimCD16+ 
단핵구 비율변화는 활액에서 거의 관찰되지 않았다. 활액 단핵구에서 
표면 CD80의 발현이 유의적 증가해 있는데 비하여, 류마티스 관절염 
환자 및 정상인의 말초혈액 단핵구에서는 CD80 발현이 관찰 되지 
않았다. 또한 막부착형 IL-15의 발현이 류마티스 환자의 단핵구에서 
증가해 있었다. 활액 유래 단핵구와 말초혈액 유래 단핵구의 TLR 발현 
정도가 상이하였으며, 특히 전반적으로 활액 유래 단핵구의 발현 정도가 
더 높게 나타났다. 활액 유래 단핵구가 어떻게 특징적 표현형을 얻게 
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되는지 알아보기 위하여, 말초혈액 유래 단핵구에 다양한 사이토카인과 
TLR ligand를 이용하여 자극하였다. TGF-β가 CD14+ 단핵구로부터 
CD16 발현을 유도하는 잠재적 인자였으며, 반면 CD80과 막부착형 
IL-15의 발현은 IFN-γ에 의해 유의적으로 증가하였다. 특히 
막부착형 IL-15의 경우는 IL-15과 함께 처리하였을 때 상승효과를 
확인할 수 있었다. 시험관배양 조건에서, 관절활액 단핵구는 말초혈액 
단핵구에 비해 유의적으로 Th17과 Th1의 반응을 증가시켰다. 위 
연구들을 통하여 류마티스 관절염 환자의 활액 내 특정 사이토카인 
환경이 활액 단핵구의 특징적 표현형을 가지게 하는 데에 역할을 할 수 
있음을 확인하였고, 이는 류마티스 관절염 환자의 염증성 T세포 반응에 
중요한 영향을 줄 수 있음을 제안하였다. 
주요 단어 ; CD16 단핵구, 류마티스 관절염, Th17, TGF-β 
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